Market-Moving News for July 15th
$AMIX
$ARTL
$DJT
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
SC 13G/A - Trump Media & Technology Group Corp. (0001849635) (Subject)
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G - Trump Media & Technology Group Corp. (0001849635) (Subject)
8-K - Trump Media & Technology Group Corp. (0001849635) (Filer)
8-K - Trump Media & Technology Group Corp. (0001849635) (Filer)
S-1/A - Autonomix Medical, Inc. (0001617867) (Filer)
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)
RF Innovations' Apex 6 Generator aligns with specifications required for Autonomix's ablation system and facilitates ongoing developmentTransaction further reinforces Autonomix's FDA regulatory pathwayTHE WOODLANDS, TX, July 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed its previously announced transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator. T
- Reuters
SARASOTA, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Trump Media & Technology Group (NASDAQ:DJT) ("TMTG") CEO Devin Nunes today issued the following statement following President-elect Trump's announcement of his intent to nominate TMTG board member Linda McMahon as Secretary of Education: "Linda is an extremely valuable board member who is amazing to work with and has been instrumental in helping TMTG navigate the capital markets, expand the Truth Social platform, and stand up our TV streaming service, Truth+. With her deep integrity and her broad experience in private business, education, philanthropy, politics, and as Administrator of the Small Business Administration, Linda is an ideal
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo's development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 (FAB
Truth+ Content Delivery Network Operating from Sites Across the Country SARASOTA, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trump Media & Technology Group (NASDAQ:DJT) ("TMTG" or the "Company"), operator of the social media platform Truth Social, is announcing today that it has completed the initial deployment of its cross-country network of data centers that power its custom-built content delivery network ("CDN"), and all planned data centers are now fully operational. The Company's CDN is the technological backbone of its new, ultra-fast TV streaming platform, Truth+. With all planned data centers now in operation, the Company will focus on expanding live TV and on-demand content, releas
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm